Pilot Study of phoP/phoQ -Deleted Salmonella enterica Serovar Typhimurium Expressing Helicobacter pylori Urease in Adult Volunteers
- 1 April 2000
- journal article
- clinical trial
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 68 (4), 2135-2141
- https://doi.org/10.1128/iai.68.4.2135-2141.2000
Abstract
Attenuated Salmonella enterica serovar Typhi has been studied as an oral vaccine vector. Despite success with attenuatedS. enterica serovar Typhimurium vectors in animals, early clinical trials of S. enterica serovar Typhi expressing heterologous antigens have shown that few subjects have detectable immune responses to vectored antigens. A previous clinical study ofphoP/phoQ-deleted S. enterica serovar Typhi expressing Helicobacter pylori urease from a multicopy plasmid showed that none of eight subjects had detectable immune responses to the vectored antigen. In an attempt to further define the variables important for engendering immune responses to vectored antigens in humans, six volunteers were inoculated with 5 × 107 to 8 × 107 CFU ofphoP/phoQ-deleted S. enterica serovar Typhimurium expressing the same antigen. Two of the six volunteers had fever; none had diarrhea, bacteremia, or other serious side effects. The volunteers were more durably colonized than in previous studies ofphoP/phoQ-deleted S. enterica serovar Typhi. Five of the six volunteers seroconverted to S. entericaserovar Typhimurium antigens and had strong evidence of anti-Salmonella mucosal immune responses by enzyme-linked immunospot studies. Three of six (three of five who seroconverted toSalmonella) had immune responses in the most sensitive assay of urease-specific immunoglobulin production by blood mononuclear cells in vitro. One of these had a fourfold or greater increase in end-point immunoglobulin titer in serum versus urease. AttenuatedS. enterica serovar Typhimurium appears to be more effective than S. enterica serovar Typhi for engendering immune responses to urease. Data suggest that this may be related to a greater stability of antigen-expressing plasmid in S. enterica serovar Typhimurium and/or prolonged intestinal colonization. Specific factors unique to nontyphoidal salmonellae may also be important for stimulation of the gastrointestinal immune system.Keywords
This publication has 46 references indexed in Scilit:
- Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteersVaccine, 1999
- Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and BVaccine, 1998
- Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteersVaccine, 1996
- Oral Immunization with Recombinant Helicobacter pylori Urease Induces Secretory IgA Antibodies and Protects Mice from Challenge with Helicobacter felisThe Journal of Infectious Diseases, 1995
- The live oral typhoid vaccine Ty21a is arpoSmutant and is susceptible to various environmental stressesFEMS Microbiology Letters, 1995
- Salmonella typhi Vaccine Strain CVD 908 Expressing the Circumsporozoite Protein of Plasmodium falciparum: Strain Construction and Safety and Immunogenicity in HumansThe Journal of Infectious Diseases, 1994
- Norfloxacin Treatment of Salmonellosis Does Not Shorten the Carrier StageScandinavian Journal of Infectious Diseases, 1990
- SAFETY, IMMUNOGENICITY, AND EFFICACY OF RECOMBINANT LIVE ORAL CHOLERA VACCINES, CVD 103 AND CVD 103-HgRThe Lancet, 1988
- Specific Immunoglobulin-Secreting Human Blood Cells After Peroral Vaccination Against Salmonella typhiThe Journal of Infectious Diseases, 1986
- A Review of Human Salmonellosis: II. Duration of Excretion Following Infection with Nontyphi SalmonellaClinical Infectious Diseases, 1984